HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Open accessAbstract
An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The synergistic effect between c-MET inhibitor and α-PD-1/PD-L1 has been verified.
“The synergistic effect between c-MET inhibitor and α-PD-1/PD-L1 has been verified [306].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [306]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · see citing works
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,733 · see citing works
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,733 · see citing works
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · see citing works
Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517 · see citing works
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,366 · see citing works
Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,279 · see citing works
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,244 · see citing works
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023 · see citing works
Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923 · see citing works
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 822 · see citing works
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 790 · see citing works
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
Trusolino, L., & Comoglio, P. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc779 · Cited by 738 · see citing works
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
植木, 孝., Kaneda, Y., Tsutsui, H., Nakanishi, K., Sawa, Y., Morishita, R., Matsumoto, K., Nakamura, T., Takahashi, H., Okamoto, E., et al. (1999) · Nature Medicine · doi:10.1038/5593 · Cited by 588 · see citing works
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1912 · Cited by 540 · see citing works
Blank, C. U., & Mackensen, A. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0272-1 · Cited by 502 · see citing works
Met provides essential signals for liver regeneration
Borowiak, M., Garratt, A. N., Wüstefeld, T., Strehle, M., Trautwein, C., & Birchmeier, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403412101 · Cited by 497 · see citing works
MET is required for the recruitment of anti-tumoural neutrophils
Finisguerra, V., Conza, G. D., Matteo, M. D., Serneels, J., Costa, S., Thompson, A. A. R., Wauters, E., Walmsley, S. R., Prenen, H., Granot, Z., et al. (2015) · Nature · doi:10.1038/nature14407 · Cited by 494 · see citing works
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476 · see citing works
Self-citationTchou, J. C., Zhao, Y., Levine, B. L., Zhang, P. J., Suhoski, M. M., Melenhorst, J. J., Kulikovskaya, I. M., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 453 · see citing works
FDA Regulation of Stem-Cell–Based Therapies
Halme, D. G., & Kessler, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmhpr063086 · Cited by 406 · see citing works
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.
Kuruvilla, A. P., Shah, R., Hochwald, G. M., Liggitt, H. D., Palladino, M. A., & Thorbecke, G. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2918 · Cited by 399 · see citing works
Mougiakakos, D., Choudhury, A., Lladser, Á., Kiessling, R. W., & Johansson, C. C. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07003-x · Cited by 392 · see citing works
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 367 · see citing works
Catenacci, D. V. T., Tebbutt, N. C., Давиденко, І., Murad, A. M., Al‐Batran, S., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30566-1 · Cited by 349 · see citing works
Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 340 · see citing works
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Renzo, M. F. D., Olivero, M., Martone, T., Maffé, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 334 · see citing works
Frigault, M. J., Lee, J., Basil, M. C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O. U., Guedan, S., McGettigan, S. E., Posey, A. D., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0186 · Cited by 324 · see citing works
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 321 · see citing works
Hilkens, C. M. U., Kaliński, P., de Boer, M., & Kapsenberg, M. L. (1997) · Blood · doi:10.1182/blood.v90.5.1920 · Cited by 292 · see citing works
Glodde, N., Bald, T., Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277 · see citing works
Lengyel, E. R., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K. Y., Salanti, G., Richter, T., Knudsen, B. S., Woude, G. F. V., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273 · see citing works
Mizuno, S., Kurosawa, T., Matsumoto, K., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1709 · Cited by 258 · see citing works
Okunishi, K., Dohi, M., Nakagome, K., Tanaka, R., Mizuno, S., Matsumoto, K., Miyazaki, J., Nakamura, T., & Yamamoto, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4745 · Cited by 244 · see citing works
Costimulation of T cells by OX40, 4-1BB, and CD27
Croft, M. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00025-x · Cited by 233 · see citing works
Takeuchi, H., Bilchik, A. J., Saha, S., Turner, R. R., Wiese, D., Tanaka, M., Kuo, C. T., Wang, H. J., & Hoon, D. S. �. (2003) · PubMed · Cited by 232 · see citing works
Dudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A., Moskovitz, M. T., Keren, S., Popovits‐Hadari, N., Urban, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.024 · Cited by 215 · see citing works
Benkhoucha, M., Santiago‐Raber, M., Schneiter, G., Chofflon, M., Funakoshi, H., Nakamura, T., & Lalive, P. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912437107 · Cited by 206 · see citing works
Mizuno, S., Matsumoto, K., Li, M.-Y., & Nakamura, T. (2005) · The FASEB Journal · doi:10.1096/fj.04-1535fje · Cited by 177 · see citing works
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 171 · see citing works
Targeting MET in cancer therapy
Mo, H., & Liu, P. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.06.002 · Cited by 163 · see citing works
Gordon, M. S., Sweeney, C. J., Mendelson, D. S., Eckhardt, S. G., Anderson, A., Beaupre, D. M., Branstetter, D. G., Burgess, T. L., Coxon, A., Deng, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1365 · Cited by 162 · see citing works
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park, S., Choi, Y., Sung, C. O., et al. (2012) · PubMed · doi:10.14670/hh-27.197 · Cited by 158 · see citing works
Balan, M., y Teran, E. M., Waaga-Gasser, A. M., Gasser, M., Choueiri, T. K., Freeman, G. J., & Pal, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612689 · Cited by 155 · see citing works
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144 · see citing works
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q. F., Shen, L., Zhang, J., Ying, X., Cheng, X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356144 · Cited by 143 · see citing works
Cañadas, I., Rojo, F., Taus, Á., Arpí, O., Arumí-Uría, M., Pijuán, L., Menéndez, S., Zazo, S., Dómine, M., Salido, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1330 · Cited by 136 · see citing works
Daveau, M., Scotté, M., François, A., et al. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10103 · Cited by 127 · see citing works
Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 126 · see citing works
Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function
Galimi, F., Cottone, E., Vigna, E., Arena, N., Boccaccio, C., Giordano, S., Naldini, L., & Comoglio, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1241 · Cited by 124 · see citing works
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122 · see citing works
Self-citationAdams, D., Harvath, L., Bottaro, D. P., Interrante, R., Catalano, G., Tanaka, Y., Strain, A. J., Hübscher, S. G., & Shaw, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7144 · Cited by 120 · see citing works
van der Voort, R., Taher, T. E. I., Keehnen, R. M. J., Smit, L., Groenink, M., & Pals, S. T. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.12.2121 · Cited by 116 · see citing works
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104 · see citing works
Self-citationCoinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic, D., Luetkens, T., & Kröger, N. M. (2013) · Leukemia · doi:10.1038/leu.2013.310 · Cited by 99 · see citing works
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Zhang, J., Medeiros, L. J., & Young, K. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00351 · Cited by 89 · see citing works
Futamatsu, H., Suzuki, J.-I., Mizuno, S., Koga, N., Adachi, S., Kosuge, H., Maejima, Y., Hirao, K., Nakamura, T., & Isobe, M. (2005) · Circulation Research · doi:10.1161/01.res.0000163016.52653.2e · Cited by 82 · see citing works
Ilangumaran, S., Villalobos-Hernandez, A., Bobbala, D., & Ramanathan, S. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.013 · Cited by 82 · see citing works
The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity
Baek, J.-H., Birchmeier, C., Zenke, M., & Hieronymus, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200729 · Cited by 79 · see citing works
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
Brahmer, J. R., Rizvi, N. A., Lutzky, J., Khleif, S. N., Blake-Haskins, A., Li, X., Robbins, P. B., Vasselli, J., Ibrahim, R. A., & Antonia, S. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8021 · Cited by 78 · see citing works
Yamaura, K., Ito, K., Tsukioka, K., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143052.45956.71 · Cited by 76 · see citing works
Mahmoudjafari, Z., Hawks, K. G., Hsieh, A. A., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.024 · Cited by 76 · see citing works
Dieras, V. C., Campone, M., Yardley, D. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv263 · Cited by 70 · see citing works
Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., Rosa, L. D., Majolino, I., Novarese, L., Rocci, A., Gambella, M., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-247 · Cited by 67 · see citing works
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
Thayaparan, T., Petrovic, R. M., Achkova, D. Y., Zabinski, T., Davies, D. M., Klampatsa, A., Parente‐Pereira, A. C., Whilding, L. M., van der Stegen, S. J. C., Woodman, N. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363137 · Cited by 67 · see citing works
The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma
Herrera, L. J., El‐Hefnawy, T., de Oliveira, P. E. Q., et al. (2005) · Neoplasia · doi:10.1593/neo.04367 · Cited by 60 · see citing works
Thompson, J., Dolcet, X., Hilton, M., et al. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.07.007 · Cited by 60 · see citing works
The impact of c-met/scatter factor receptor on dendritic cell migration
Kurz, S. M., Diebold, S. S., Hieronymus, T., Gust, T. C., Bartůněk, P., Sachs, M., Birchmeier, W., & Zenke, M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7 · Cited by 58 · see citing works
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Kumai, T., Matsuda, Y., Ohkuri, T., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.976077 · Cited by 49 · see citing works
Schag, K., Schmidt, S. M., Müller, M., Weinschenk, T., Appel, S., Weck, M. M., Grünebach, F., Stevanović, S., Rammensee, H., & Brossart, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0640 · Cited by 46 · see citing works
New strategies in immunotherapy for non-small cell lung cancer.
Carrizosa, D. R., & Gold, K. A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.05 · Cited by 46 · see citing works
PD-L1 inhibitors in the pipeline: Promise and progress
Vanella, V., Festino, L., Strudel, M., Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1365209 · Cited by 43 · see citing works
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
Sun, Z., Wu, Y. M., Hou, W.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16173 · Cited by 41 · see citing works
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 40 · see citing works
Self-citationSinghal, E., Kumar, P., & Sen, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271247 · Cited by 40 · see citing works
Sabari, J. K., Montecalvo, J., Chen, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8512 · Cited by 38 · see citing works
Hirsch, F. R., Govindan, R., Zvirbule, Z., Braiteh, F., Rittmeyer, A., Belda-Iniesta, C., Isla, D., Cosgriff, T. M., Boyer, M., Ueda, M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.011 · Cited by 35 · see citing works
Morgillo, F., Amendola, G., Corte, C. M. D., Giacomelli, C., Botta, L., Maro, S. D., Messere, A., Ciaramella, V., Taliani, S., Marinelli, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00794 · Cited by 30 · see citing works
Self-citationHepatocyte growth factor activates several transduction pathways in rat pancreatic acini
Aparicio, I. M., Garcı́a, L. J., Andreolotti, A. G., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.007 · Cited by 29 · see citing works
Singhal, E., & Sen, P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.006 · Cited by 24 · see citing works
Xu, Q., Nakayama, M., Suzuki, Y., et al. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00216.2011 · Cited by 20 · see citing works
Drilon, A., Ou, S. I., Clark, J. W., Camidge, D. R., Socinski, M. A., Weiss, J. M., Solomon, B., Riely, G. J., Heist, R. S., Shapiro, G. I., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.512 · Cited by 15 · see citing works
de Marinis, F., Ciardiello, F., Baas, P., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000298 · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers · doi:10.3390/cancers14194933 · Cited by 24 · see citing works
- Authors
- Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
- Corresponding author
- Papaccio, Federica
- Morgillo, Floriana
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-14
- Volume
- 19
- Issue
- 11
- Pages
- 3595
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6274701
- OpenAlex
- W2901379455
- Cited by
- 110
- References
- 93
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 13 · 2023: 13 · 2022: 24 · 2021: 21 · 2020: 19 · 2019: 6 · 2016: 1
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocyte growth factor, c-Met, cancer immunotherapy, tumor immune microenvironment, dendritic cells, immunosuppression, PD-1/PD-L1 blockade, combination therapy, drug design, cell therapy
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Hepatocyte Growth Factor, Proto-Oncogene Proteins c-met
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
